



The new issue of Massive Bio magazine is now available

The new issue of Massive Bio magazine, which explores the latest developments in oncology and clinical trials, is now available.

NEW YORK, NEW YORK, USA, February 2, 2023 /EINPresswire.com/ -- [Massive Bio](#), which uses artificial intelligence-based technology to help cancer patients gain access to potentially lifesaving oncology therapies, announces the publication of a new issue of Massive Bio magazine. Each edition of Massive Bio magazine explores the latest developments in the fields of oncology and clinical trials while keeping readers up to date on our mission to improve the lives of cancer patients. In the latest issue of Massive Bio magazine, readers will learn about artificial intelligence's role in the effort to find a cure for cancer, the link between cancer and climate change, new approaches to conducting clinical trials, and much more.

Can artificial intelligence cure cancer?

Artificial intelligence (AI) is reshaping our lives as the “brains” behind innovations ranging from countertop digital assistants to self-driving cars. In the new issue of Massive Bio magazine, readers will confront an important question: Is this technology powerful enough to achieve a goal that has eluded humankind for centuries—find a cure for cancer? In “Can AI Cure Cancer?” we share some of the many ways that AI is already having a crucial impact on cancer research and care, including its role in driving Massive Bio's SYNERGY-AI platform, which matches patients to clinical trials with unparalleled speed and precision.

How does the climate crisis affect cancer?

Recent research suggests that changes in our environment brought on by the warming of the planet are causing some forms of cancer to become more common. The latest issue of Massive Bio magazine explores the links between climate change and several common malignancies, including lung cancer, melanoma, gastrointestinal cancers, and others.

In addition, the new issue of Massive Bio magazine features an interview with Erkan Terzi, the company's chief marketing officer and creator of the social media campaign I Have Cancer, which was launched by Massive Bio in November. Readers will also learn about one breast cancer patient's decision to enter a clinical trial, the latest information about cervical cancer, and innovations from the world of clinical research, among other topics of interest to cancer patients and their loved ones. Massive Bio magazine is available in English, Italian, Spanish, Polish, and Turkish and can be read on the company website ([massivebio.com](#)) and on magazine

platforms.

About Massive Bio

Massive Bio empowers cancer patients to find the best treatment options and provides convenient access and enrollment services to worldwide oncology clinical trials powered by advanced artificial intelligence. Founded on the belief that all people should have equal access to cutting-edge treatments, Massive Bio combines a best-in-class artificial intelligence platform with concierge-level services, removing many of the barriers cancer patients face in enrolling and participating in clinical trials. Headquartered in New York City and including over 100,000 patients on its platform, Massive Bio operates in 12 countries.

Merve Sahin

Massive Bio

+1 844-627-7246

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/613081517>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.